Fact Sheet


Catalog excerpts

Fact Sheet - 1

Market Snapshot NASDAQ ticker symbol Stock price (05/11/22) 52-week range Market capitalization Shares outstanding Institutional ownership Insider ownership Fiscal year-end ABOUT SENSUS HEALTHCARE Sensus Healthcare, Inc. is a medical device company specializing in clinically effective, non-invasive, minimally invasive and costeffective treatments for both oncological and non-oncological conditions. Sensus offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers (NMSC) and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. The addition of aesthetic dermatology products expands its portfolio of innovative medical device products, allowing Sensus to provide revolutionary treatment options to enhance the quality of life of patients around the world. INVESTMENT HIGHLIGHTS Safe, effective, patented and reimbursed products with patient, physician and payer benefits. NMSC patients have excellent clinical outcomes, no downtime and superior aesthetics with SRT vs. Mohs surgery. SRT physicians expand their practices and improve efficiencies, while increased patient visits heighten the opportunity for cross-selling treatments; Payers benefit from reimbursement comparable to Mohs, without the extra expenses for wound care and reconstructive surgery. Reimbursement codes were revalued upwards by as much as 66% on 1/1/21, providing additional incentives to customers. Large U.S. market with OUS and pipeline opportunities. In the U.S. there are about 1,000 Mohs surgeons, 14,000 dermatologists, 6,500 plastic surgeons and 5,500 radiation oncologists. Sensus operates a direct salesforce in the U.S. with distributors in China and certain other international markets. All SRT systems have regulatory clearance in the U.S., and the SRT-100 is cleared in Canada, China, the EU, Israel, and Mexico, among others, with expectations for additional clearances in Latin America and Asia. In October 2021, Sensus’ license in China was renewed for five more years. Sensus plans to broaden SRT treatment indications to include other skin conditions. A 2021 leasing program has improved customer ROI on the premium SRT-100 Vision™ and increased ASPs. Well-defined customer base to treat a rapidly growing patient population. The primary customers for SRT systems are dermatologists and plastic surgeons, with radiation oncologists representing an additional market opportunity. It is projected that there will be more than 71 million new cases of skin cancer in the United States alone by 2032, and the number of NMSC cases is already three times all other cancers combined. Acquired and developed new products to strengthen the portfolio. Its 2020 acquisition of a mobile aesthetic laser company brings an additional recurring revenue stream and new customers across Florida. In 2022, Sensus added the TransDermal Infusion System™ distribution for needle-free delivery of aesthetic medicines. In addition, Sentinel™, Sensus’ powerful I.T. platform provides the company with opportunity for shared revenue while providing customers with asset management capabilities, as well as HIPAA compliant Patient Data collection. Furthermore, growth in service contracts provides a further source of high-margin recurring revenues. Strong financial momentum. Net income and EPS were $5.3 million and $0.32 per share, respectively in 4Q21, and 2021 net income and EPS were $4.1 million and $0.25, respectively on revenues of $27.0 million. Revenue for 1Q22 was $10.3 million, up 237% with EPS from operations of $0.20. Cash and equivalents at 3/31/22 were $32.8 million, including $15.0 million from the sale of a non-core asset. Additionally, the board of directors approved a $3.0 million share repurchase program. Executive team has strong record with capital equipment business models. Led by industry veteran CEO Joseph Sardano, the executive team’s experience includes capital equipment sales at GE, Siemens, Toshiba, Hologic and others. THE FASTEST-GROWING & MOST-PREVALENT CANCER: NON-MELANOMA SKIN CANCER CACANCERCANCER Mohs (Surgical) Treatment Option ▪ Invasive and complicated procedure that requires a highly skilled surgeon ▪ Often results in poor cosmetic outcomes in facial areas, forcing patients to consider reconstructive surgery and wound care ▪ Preexisting conditions (i.e., diabetes, heart conditions) increase the risk of poor healing outcomes ▪ Lower limb (e.g., shin) and scalp are especially hard-to-heal areas ▪ Quality-of-life is adversely impacted, especially during the recovery period SRT (Non-Surgical) Treatment Option ▪ ▪ ▪ ▪ ▪ ▪ ▪ Comparable cure rates to Mohs, as supported by published clinical studies Non-invasive procedure with no lifestyle impact No anesthesia, no cutting and no pain No comorbidity limitations to patient selection Ideal to treat challenging sites on the body (e.g., lower limb, scalp) Multiple patient visits (10-20) allow the practice to cross-sell products and procedures Lower healthcare

Open the catalog to page 1
Fact Sheet - 2

KELOIDS: A POTENTIALLY LARGER MARKET THAN NMSC ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ Keloids are an area of irregular fibrous tissue formed at the site of a scar or injury The NIH estimates that 11+ million people worldwide are living with keloid scars Genetic predisposition to keloids among those of African, Latin and Asian descent In 2017 Sensus received keloid clearance in China Current treatment methods may reduce the size of the keloid but are not a permanent solution, and most patients are informed by their physicians “there is no remedy” Recurrence rates of keloids are very high, up to 90%, and keloids...

Open the catalog to page 2

All Sensus Healthcare catalogs and technical brochures